MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Alkermes PLC

Closed

SectorHealthcare

29.22 -0.48

Overview

Share price change

24h

Current

Min

29.01

Max

29.57

Key metrics

By Trading Economics

Income

-124M

22M

Sales

-123M

307M

P/E

Sector Avg

14.138

39.857

EPS

0.291

Profit margin

7.329

Employees

1,800

EBITDA

-168M

14M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+38.08% upside

Dividends

By Dow Jones

Next Earnings

29 lip 2025

Market Stats

By TradingEconomics

Market Cap

-832M

5B

Previous open

29.7

Previous close

29.22

News Sentiment

By Acuity

50%

50%

154 / 376 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Alkermes PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 lip 2025, 21:01 UTC

Earnings

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 lip 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

18 lip 2025, 20:50 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

18 lip 2025, 20:50 UTC

Market Talk
Earnings

Basic Materials Roundup: Market Talk

18 lip 2025, 20:46 UTC

Earnings

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 lip 2025, 20:39 UTC

Acquisitions, Mergers, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 lip 2025, 20:36 UTC

Earnings

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 lip 2025, 20:16 UTC

Acquisitions, Mergers, Takeovers

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 lip 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 lip 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18 lip 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 lip 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 lip 2025, 18:24 UTC

Earnings

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 lip 2025, 18:19 UTC

Earnings

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 lip 2025, 18:11 UTC

Acquisitions, Mergers, Takeovers

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 lip 2025, 18:11 UTC

Earnings

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 lip 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 lip 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 lip 2025, 16:28 UTC

Acquisitions, Mergers, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 lip 2025, 16:22 UTC

Earnings

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 lip 2025, 16:20 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

18 lip 2025, 16:20 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

18 lip 2025, 16:20 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

18 lip 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Energy & Utilities Roundup: Market Talk

18 lip 2025, 16:20 UTC

Market Talk
Earnings

Basic Materials Roundup: Market Talk

18 lip 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 lip 2025, 16:04 UTC

Earnings

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 lip 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18 lip 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 lip 2025, 15:47 UTC

Market Talk
Earnings

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Peer Comparison

Price change

Alkermes PLC Forecast

Price Target

By TipRanks

38.08% upside

12 Months Forecast

Average 40.54 USD  38.08%

High 46 USD

Low 34 USD

Based on 14 Wall Street analysts offering 12 month price targets forAlkermes PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

14 ratings

9

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

27.95 / 30.91Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

154 / 376 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.